@article{5514678d32714a0a9d4d1bf627b8a7b8,
title = "Common variable immunodeficiency: a new look at an old disease",
abstract = "Primary immunodeficiencies comprise many diseases caused by genetic defects primarily affecting the immune system. About 150 such diseases have been identified with more than 120 associated genetic defects. Although primary immunodeficiencies are quite rare in incidence, the prevalence can range from one in 500 to one in 500 000 in the general population, depending on the diagnostic skills and medical resources available in different countries. Common variable immunodeficiency (CVID) is the primary immunodeficiency most commonly encountered in clinical practice, and appropriate diagnosis and management of patients will have a significant effect on morbidity and mortality as well as financial aspects of health care. Advances in diagnostic laboratory methods, including B-cell subset analysis and genetic testing, coupled with new insights into the molecular basis of immune dysfunction in some patients with CVID, have enabled advances in the clinical classification of this heterogeneous disease.",
author = "Park, {Miguel A.} and Li, {James T.} and Hagan, {John B.} and Maddox, {Daniel E.} and Abraham, {Roshini S.}",
note = "Funding Information: MAP and JBH are coinvestigators in a multicentre extension study on the safety and efficacy of IgPro10 in patients with primary immune deficiency sponsored by ZLB Behring; MAP, JBH, and DEM are coinvestigators in a phase III open-label, prospective, multicentre study of the efficacy, tolerability, safety, and pharmacokinetics of immune globulin subcutaneous IgPro20 in patients with primary immunodeficiency sponsored by ZLB Behring; MAP, JTL and JBH were coinvestigators in ZLB03_002CR, a multicentre study of the efficacy, safety, and pharmacokinetics of IgPro10 in patients with primary immunodeficiency, sponsored by ZLB Behring—none of the investigators received personal funding for their involvement in the above studies. RSA received a USIDNET (US Immunodeficiency Network funded by the NIH) and Jeffrey Modell Foundation travel scholarship to attend the IUIS/WHO meeting on primary immunodeficiencies in 2007.",
year = "2008",
doi = "10.1016/S0140-6736(08)61199-X",
language = "English (US)",
volume = "372",
pages = "489--502",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9637",
}